-
Je něco špatně v tomto záznamu ?
Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding
M. Hozman, S. Hassouna, L. Grochol, P. Waldauf, T. Hracek, BZ. Pazdiorova, S. Adamec, P. Osmancik
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
- Publikační typ
- časopisecké články MeSH
The association between antithrombotics (ATs) and the risk of gastrointestinal bleeding is well known; however, data regarding the influence of ATs on outcomes are scarce. The goals of this study are: (i) to assess the impact of prior AT therapy on in-hospital and 6-month outcomes and (ii) to determine the re-initiation rate of the ATs after a bleeding event. All patients with upper gastrointestinal bleeding (UGB) who underwent urgent gastroscopy in three centres from 1 January 2019 to 31 December 2019 were retrospectively analysed. Propensity score matching (PSM) was used. Among 333 patients [60% males, mean age 69.2 (±17.3) years], 44% were receiving ATs. In multivariate logistic regression, no association between AT treatment and worse in-hospital outcomes was observed. Development of haemorrhagic shock led to worse survival [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.9-10.2, P < 0.001; after PSM: OR 5.3, 95% CI 1.8-15.7, P = 0.003]. During 6-months follow-up, higher age (OR 1.0, 95% CI 1.0-1.1, P = 0.002), higher comorbidity (OR 1.4, 95% CI 1.2-1.7, P < 0.001), a history of cancer (OR 3.6, 95% CI 1.6-8.1, P < 0.001) and a history of liver cirrhosis (OR 2.2, 95% CI 1.0-4.4, P = 0.029) were associated with higher mortality. After a bleeding episode, ATs were adequately re-initiated in 73.8%. Previous AT therapy does not worsen in-hospital outcomes in after UGB. Development of haemorrhagic shock predicted poor prognosis. Higher 6-month mortality was observed in older patients, patients with more comorbidities, with liver cirrhosis and cancer.
Cardiocenter Hospital Karlovy Vary 360 01 Karlovy Vary Czech Republic
Department of Gastroenterology Hospital Cheb 350 02 Cheb Czech Republic
Department of Gastroenterology Hospital Karlovy Vary 360 01 Karlovy Vary Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009650
- 003
- CZ-PrNML
- 005
- 20250415110514.0
- 007
- ta
- 008
- 230707s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurheartjsupp/suad103 $2 doi
- 035 __
- $a (PubMed)37234230
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hozman, Marek $u Cardiocenter, Hospital Karlovy Vary, 360 01 Karlovy Vary, Czech Republic
- 245 10
- $a Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding / $c M. Hozman, S. Hassouna, L. Grochol, P. Waldauf, T. Hracek, BZ. Pazdiorova, S. Adamec, P. Osmancik
- 520 9_
- $a The association between antithrombotics (ATs) and the risk of gastrointestinal bleeding is well known; however, data regarding the influence of ATs on outcomes are scarce. The goals of this study are: (i) to assess the impact of prior AT therapy on in-hospital and 6-month outcomes and (ii) to determine the re-initiation rate of the ATs after a bleeding event. All patients with upper gastrointestinal bleeding (UGB) who underwent urgent gastroscopy in three centres from 1 January 2019 to 31 December 2019 were retrospectively analysed. Propensity score matching (PSM) was used. Among 333 patients [60% males, mean age 69.2 (±17.3) years], 44% were receiving ATs. In multivariate logistic regression, no association between AT treatment and worse in-hospital outcomes was observed. Development of haemorrhagic shock led to worse survival [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.9-10.2, P < 0.001; after PSM: OR 5.3, 95% CI 1.8-15.7, P = 0.003]. During 6-months follow-up, higher age (OR 1.0, 95% CI 1.0-1.1, P = 0.002), higher comorbidity (OR 1.4, 95% CI 1.2-1.7, P < 0.001), a history of cancer (OR 3.6, 95% CI 1.6-8.1, P < 0.001) and a history of liver cirrhosis (OR 2.2, 95% CI 1.0-4.4, P = 0.029) were associated with higher mortality. After a bleeding episode, ATs were adequately re-initiated in 73.8%. Previous AT therapy does not worsen in-hospital outcomes in after UGB. Development of haemorrhagic shock predicted poor prognosis. Higher 6-month mortality was observed in older patients, patients with more comorbidities, with liver cirrhosis and cancer.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hassouna, Sabri $u Cardiocenter, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Ruska 87, 100 00 Prague, Czech Republic $7 xx0331110
- 700 1_
- $a Grochol, Lukas $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady,100 00 Prague, Czech Republic
- 700 1_
- $a Waldauf, Petr $u Department of Anaesthesia and Intensive Care, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
- 700 1_
- $a Hracek, Tomas $u Department of General Surgery, 3rd Faculty of Medicine, Charles University, Faculty Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
- 700 1_
- $a Pazdiorova, Blanka Zborilova $u Department of Gastroenterology, Hospital Karlovy Vary, 360 01 Karlovy Vary, Czech Republic
- 700 1_
- $a Adamec, Stanislav $u Department of Gastroenterology, Hospital Cheb, 350 02 Cheb, Czech Republic
- 700 1_
- $a Osmancik, Pavel $u Cardiocenter, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Ruska 87, 100 00 Prague, Czech Republic
- 773 0_
- $w MED00005247 $t European heart journal supplements $x 1520-765X $g Roč. 25, Suppl E (2023), s. E25-E32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37234230 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20250415110521 $b ABA008
- 999 __
- $a ok $b bmc $g 1958453 $s 1195914
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 25 $c Suppl E $d E25-E32 $e 20230524 $i 1520-765X $m European heart journal supplements $n Eur Heart J Suppl $x MED00005247
- LZP __
- $a Pubmed-20230707
